131 related articles for article (PubMed ID: 36856058)
41. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
[TBL] [Abstract][Full Text] [Related]
42. Identification of highly active natural thyroid hormone receptor agonists by pharmacophore-based virtual screening.
Tang S; Sun L; Wang F
J Biomol Struct Dyn; 2021 Feb; 39(3):901-910. PubMed ID: 31997713
[TBL] [Abstract][Full Text] [Related]
43. Pharmacophore model-based virtual screening, docking, biological evaluation and molecular dynamics simulations for inhibitors discovery against
Naz S; Farooq U; Khan S; Sarwar R; Mabkhot YN; Saeed M; Alsayari A; Muhsinah AB; Ul-Haq Z
J Biomol Struct Dyn; 2021 Feb; 39(2):610-620. PubMed ID: 31937192
[TBL] [Abstract][Full Text] [Related]
44. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, ADMET, and Molecular Dynamics (MD) Simulation of Potential Inhibitors of PD-L1 from the Library of Marine Natural Products.
Luo L; Zhong A; Wang Q; Zheng T
Mar Drugs; 2021 Dec; 20(1):. PubMed ID: 35049884
[TBL] [Abstract][Full Text] [Related]
45. Discovery of potential inhibitors for stat3: ligand based 3D pharmacophore, virtual screening, molecular docking, dynamic studies and
Lakshmanan K; T K P; K Pai SR; Rajagopal K; Byran G
J Biomol Struct Dyn; 2022; 40(21):11320-11338. PubMed ID: 34463213
[TBL] [Abstract][Full Text] [Related]
46. Rational approach to identify newer caspase-1 inhibitors using pharmacophore based virtual screening, docking and molecular dynamic simulation studies.
Patel S; Modi P; Chhabria M
J Mol Graph Model; 2018 May; 81():106-115. PubMed ID: 29549805
[TBL] [Abstract][Full Text] [Related]
47. Design and development of novel potential inhibitors of the human USP21 enzyme using a pharmacophore-based virtual screening technique.
Roy A; Luharuka S; Paul I; Ray S
J Mol Recognit; 2023 Jul; 36(7):e3023. PubMed ID: 37096811
[TBL] [Abstract][Full Text] [Related]
48. Targeting p53-MDM2 interactions to identify small molecule inhibitors for cancer therapy: beyond "Failure to rescue".
Chukwuemeka PO; Umar HI; Iwaloye O; Oretade OM; Olowosoke CB; Elabiyi MO; Igbe FO; Oretade OJ; Eigbe JO; Adeojo FJ
J Biomol Struct Dyn; 2022; 40(19):9158-9176. PubMed ID: 33988074
[TBL] [Abstract][Full Text] [Related]
49. Identification of Four New Chemical Series of Small Drug-Like Natural Products as Potential Neuropilin-1 Inhibitors by Structure-Based Virtual Screening: Pharmacophore-Based Molecular Docking and Dynamics Simulation.
Sabki A; Khelifi L; Kameli A; Baali S
Chem Biodivers; 2023 Mar; 20(3):e202200933. PubMed ID: 36799050
[TBL] [Abstract][Full Text] [Related]
50. Pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation for identification of potential ERK inhibitors.
Tian Y; Zhang M; Heng P; Hou H; Wang B
J Biomol Struct Dyn; 2024; 42(4):2153-2161. PubMed ID: 37129289
[TBL] [Abstract][Full Text] [Related]
51. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
52. Identification of human tau-tubulin kinase 1 inhibitors: an integrated e-pharmacophore-based virtual screening and molecular dynamics simulation.
Jana S; Singh SK
J Biomol Struct Dyn; 2020 Feb; 38(3):886-900. PubMed ID: 30829560
[TBL] [Abstract][Full Text] [Related]
53. Identification of Novel Src Inhibitors: Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.
Zhang Y; Zhang TJ; Tu S; Zhang ZH; Meng FH
Molecules; 2020 Sep; 25(18):. PubMed ID: 32911607
[TBL] [Abstract][Full Text] [Related]
54. 3D QSAR pharmacophore-based virtual screening for the identification of potential inhibitors of tyrosinase.
Ghayas S; Ali Masood M; Parveen R; Aquib M; Farooq MA; Banerjee P; Sambhare S; Bavi R
J Biomol Struct Dyn; 2020 Jul; 38(10):2916-2927. PubMed ID: 31334690
[TBL] [Abstract][Full Text] [Related]
55. Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors.
Hammad S; Bouaziz-Terrachet S; Meghnem R; Meziane D
J Mol Model; 2020 May; 26(6):160. PubMed ID: 32472293
[TBL] [Abstract][Full Text] [Related]
56. Identification of potential leukocyte antigen-related protein (PTP-LAR) inhibitors through 3D QSAR pharmacophore-based virtual screening and molecular dynamics simulation.
Du S; Yang B; Wang X; Li WY; Lu XH; Zheng ZH; Ma Y; Wang RL
J Biomol Struct Dyn; 2020 Sep; 38(14):4232-4245. PubMed ID: 31588870
[TBL] [Abstract][Full Text] [Related]
57. Developing new PI3Kγ inhibitors by combining pharmacophore modeling, molecular dynamic simulation, molecular docking, fragment-based drug design, and virtual screening.
Zhu J; Sun D; Li X; Jia L; Cai Y; Chen Y; Jin J; Yu L
Comput Biol Chem; 2023 Jun; 104():107879. PubMed ID: 37182359
[TBL] [Abstract][Full Text] [Related]
58. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Rathi E; Kumar A; Kini SG
J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
[TBL] [Abstract][Full Text] [Related]
59. Pharmacophore-based virtual screening, molecular docking, and molecular dynamics studies for the discovery of novel FLT3 inhibitors.
Ouassaf M; Daoui O; Alam S; Elkhattabi S; Belaidi S; Chtita S
J Biomol Struct Dyn; 2023; 41(16):7712-7724. PubMed ID: 36106982
[TBL] [Abstract][Full Text] [Related]
60. Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches.
Nada H; Lee K; Gotina L; Pae AN; Elkamhawy A
Comput Biol Med; 2022 Mar; 142():105217. PubMed ID: 35032738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
